Results 191 to 200 of about 25,225,361 (379)

Characterization of monoclonal antibodies to human immunodefiency virus type 1 gp41 by HIV-1 polypeptides expressed inEscherichia coli [PDF]

open access: bronze, 1990
Clara Larcher   +7 more
openalex   +1 more source

Molecular epidemiological analysis of HIV-1 in Kazakhstan in 2009-2013

open access: yesВопросы вирусологии, 2015
In this study pol gene analysis of 205 HIV-1 samples collected in Kazakhstan in 2009 and 2012-2013 was carried out. CRF02_AG variant is dominating in almaty and actively circulates in East Kazakhstan Province.
I. A. Lapovok   +8 more
doaj  

Neopterin Changes during Zidovudine Treatment of HIV-1 Infection [PDF]

open access: hybrid, 1990
J. Hutterer   +5 more
openalex   +1 more source

HLA-associated susceptibility to HIV-1 infection

open access: green, 1992
Giovanna Fabio   +9 more
openalex   +2 more sources

Chicken Pulmonary MicroRNAs Targeting the PB2 (Segment 1) of Avian Influenza Virus

open access: yesAnimal Research and One Health, EarlyView.
The PB2 segment of H5N1 is essential for replication and host adaptation. We screened 200 miRNAs and identified five (gga‐miR‐17‐3p, gga‐miR‐29a‐5p, gga‐miR‐1718, gga‐miR‐16c‐5p, and gga‐miR‐1744‐5p) using thermodynamic stability of heteroduplex, seed sequence complementarity, conservation, and accessibility, offering insights into host antiviral ...
Akanksha Choudhary   +7 more
wiley   +1 more source

Expert Perspective: Diagnosis and Treatment of Castleman Disease

open access: yesArthritis &Rheumatology, EarlyView.
Castleman disease (CD) is a major diagnostic challenge for rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region, whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y. C. Chen   +2 more
wiley   +1 more source

Low Education as a Possible Risk Factor for Cognitive Abnormalities in HIV-1

open access: bronze, 1993
Paul Satz   +11 more
openalex   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

Home - About - Disclaimer - Privacy